|Year : 2013 | Volume
| Issue : 1 | Page : 17-21
Immunohistochemical expression of HER2 in urothelial bladder carcinoma and its correlation with p53 and p63 expression
Slim Charfi1, Abdelmajid khabir1, Hela Mnif1, Sameh Ellouze1, Mohamed Nabil Mhiri2, Tahya Boudawara-Sellami1
1 Department of Pathology, CHU Habib Bourguiba, Sfax, Tunisia
2 Department of Urology, CHU Habib Bourguiba, Sfax, Tunisia
|Date of Web Publication||24-Jan-2018|
Laboratoire d'anatomie et de cytologie pathologiques, CHU Habib Bourguiba, Route ElAin Km 0,5, 3029 Sfax
Source of Support: None, Conflict of Interest: None
This study assessed the human epidermal growth factor receptor-2 (HER2) protein expression in urothelial bladder carcinoma and its relationship with p53 and p63 expression. In 151 patients, paraffin-embedded tissues of transurethral resection or cystectomy were evaluated by immunohistochemistry (IHC), using antibodies against HER2, p53 and p63. HER2 overexpression (score 3+), p53 overexpression and decreased expression of p63 were detected in 14 (9.3%), 48 (31.8%) and 58 (38.4%) tumors, respectively. HER2 overexpression, p53 overexpression and decreased expression of p63 were associated with high tumor grade (p = 0.0002, p = 0.0002 and p = 0.046, respectively) and advanced TNM stage (p = 0.017, p = 0.012 and p = 0.001, respectively) of urothelial bladder carcinoma. In univariate analysis HER2 overexpression was significantly associated with decreased expression of p63 (p = 0.037). In multivariate analysis, only tumor grade was correlated with HER2 overexpression (p = 0.006). In this study, HER2 is overexpressed in 9.3% of urothelial bladder carcinomas. HER2 overexpression was strongly correlated with tumor grade but not with TNM stage, p53 and p63. The development of target therapies using anti-HER2 and the identification of patients which who benefit from those therapies need further studies.
Keywords: HER2, p53, p63, Immunohistochemistry, Urothelial bladder carcinoma
|How to cite this article:|
Charfi S, khabir A, Mnif H, Ellouze S, Mhiri MN, Boudawara-Sellami T. Immunohistochemical expression of HER2 in urothelial bladder carcinoma and its correlation with p53 and p63 expression. J Microsc Ultrastruct 2013;1:17-21
|How to cite this URL:|
Charfi S, khabir A, Mnif H, Ellouze S, Mhiri MN, Boudawara-Sellami T. Immunohistochemical expression of HER2 in urothelial bladder carcinoma and its correlation with p53 and p63 expression. J Microsc Ultrastruct [serial online] 2013 [cited 2020 Apr 6];1:17-21. Available from: http://www.jmau.org/text.asp?2013/1/1/17/223893
| 1. Introduction|| |
Urothelial bladder carcinoma represents in Tunisia the first urological cancer. Its incidence is estimated at 13.1–19 per 100,000 ,. Several factors are involved in determining prognosis and treatment selection. Tumor grade and TNM stage are two independent factors which determine the treatment strategy. The human epidermal growth factor receptor-2 (HER2) is known to contribute to physiologic mechanisms of cell proliferation by an intrinsic tyrosine kinase activity. The assessment of the HER2 status is crucial for the management of breast cancer, for both prognosis and prediction of the response to targeted therapies. In urothelial bladder carcinoma, immunohistochemical HER2 expression varies among different studies, ranging from 9 to 81% ,,,,,,,,,,. Recently a large multicenter series investigating invasive bladder carcinoma has shown HER2 overexpression in 9.2% . Several studies have demonstrated that p53 and p63 are two prognostic markers for urothelial carcinoma associated to tumor progression and poor clinical outcome ,,,,. This study explored whether immunohistochemical HER2 expression is related to these two markers (p53 and p63).
| 2. Materials and methods|| |
2.1. Study population and tissue specimens
A series of 151 tumors from 151 patients (130 men and 21 women; mean age 65.94 ± 12.8 years, range 26–101 years) diagnosed with primary urothelial carcinoma of the urinary bladder was selected from the Habib Bourguiba Pathology Department files from 2006 to 2008. Paraffin-embedded tissues were obtained after transurethral resection for bladder tumor or cystectomy. Histological examination on hematoxylin–eosin (H&E) stained slides was carried out confirming the diagnosis urothelial cell carcinoma. The TNM classification was used for tumor staging and the 2004 WHO classification for tumor grading ,. Tumor grade and TNM stage of these tumors were summarized in [Table 1].
Before immunostaining, two pathologists (SC and AK) reviewed hematoxylin–eosin stained slides from the original paraffin-embedded blocks in each case. One section representing the most invasive areas of each tumor was selected. Briefly, 4 μm-thick sections were cut from each paraffin block, mounted on poly-L-lysinecoated slides, fixed in acetone for 10 min, and left to dry overnight at 37°C. Slides were deparaffinized in xylene followed by absolute ethanol and subsequent rehydration in graded ethanol. The sections were then pre-treated with 3% hydrogen peroxide for 10 min to inactivate endogenous peroxides and washed in phosphate-buffered saline (PBS) solution. Heat-induced antigen retrieval was performed using epitope retrieval solution (DAKO) at 95 °C for 40 min. After heating, slides were allowed to cool down to room temperature and were briefly washed with PBS. Blocking solution (Protein Block Serum: 0.25% Casein in PBS containing Carrier Protein and NaN3; DAKO) was used for 5 min to prevent nonspecific immunostaining. Immunohistochemical staining was performed using the streptavidin-biotin peroxidase system. Slides were incubated for 30 min at room temperature with anti-HER2 (clone CB11, Novocastra, Newcastle upon Tyne, UK; dilution, 1/40), anti-p53 (Clone: DO-7, code: M7001, DAKO; dilution, 1/50) and anti-p63 (Clone: A4A, code: M7247, DAKO; dilution, 1/40), then washed with PBS before applying the biotinylated secondary antibody (anti-rabbit, DAKO) for 5 min. Sections were incubated with the streptavidin-biotin complex reagent (Universal Quick Kit, DAKO) for 15 min and developed with 3,3’-diaminobenzidine tetrahydrochloride (DAB) for 30 min. Finally, tissues sections were counterstained by Mayer's hematoxylin, dehydrated, and mounted (DAKO). Internal/external, positive/negative controls for each antibody were used for validation of the reactions.
2.3. Evaluation of immunohistochemical staining
HER2 positivity was assessed using the ASCO scoring system, evaluating only membranous staining . The level of HER2 protein expression was assessed semiquantitatively by the intensity and percentage of staining and scored on a scale of 0–3+. Only tumors with score 3+ are categorized as positive. A score of 1+ was defined as barely perceptible membrane staining in >10% of cells, a score of 2+ was defined as weak-to-moderate complete membrane staining present in >10% of tumor cells, and a score of 3+ was defined as strong complete membrane staining in >30% of tumor cells. A cytoplasmic staining was considered nonspecific. Only nuclear immunostaining for p53 and p63 was considered positive. Regarding p53, tumors showing immunoreactivity of more 10% of tumor cell nuclei were considered positive (p53 overexpression), in accordance with the practice used in previous studies because it has been shown that accumulation of p53 protein in 10% or more of the tumor cell nuclei strongly correlates with mutations in the p53 gene ,,. For p63 immunoreactivity, a cut off of 90% was used considering tumors with immunoreactivity less than 90% of cell as decreased expression of p63 and staining of more than 90% of cells as normal . All fields of the section has been analysed by two pathologists (S.C. and A.K.) using multi viewing microscope. When the results were different, agreement was reached with careful discussion.
2.4. Statistical analysis
Data available for statistical evaluation was performed with Statistical Package for the Social Sciences SPSS (version 17.0, IBM, Chicago, IL, USA) for windows software. Initially, a descriptive analysis of all collected variables was performed. The correlation between expression of HER2, p53, p63 and tumor grade and TNM stage were assessed with Fisher's exact and chi-square tests. The same tests were used for the correlation between p53, p63 and HER2 expression. For multivariate analysis, binary logistic regression was performed incorporating significant parameters by the univariate analysis. All differences were deemed significant at the level of p <0.05.
| 3. Results|| |
3.1. Expression of HER2 and association with pathologic characteristics
Strong protein expression (3+) was observed in 14 of 151 tumors (9.3%) [Figure 1]. An immunohistochemistry 0/1+ score was detected in respectively 55 (36.4%) and 61 (40.4%). 21 cases (13.9%) were scored as 2+. HER2 overexpression was significantly associated with the tumor grade (p = 0.0002) and TNM stage (p = 0.017) [Table 2].
|Figure 1: Strong and diffuse HER2 immunostaining surrounding the entire cell membrane (score 3+) (HER2 400×).|
Click here to view
|Table 2: Association of HER2, p53 and p63 immunostaining with histopathological parameters.|
Click here to view
3.2. Expression of p53 and p63 and association with pathologic characteristics [Table 2]
Overexpression of p53 was observed in 48 of 151 tumors (31.8%). Decreased expression of p63 expression was found in 58 of 151 tumors (38.4%) [Figure 2] and [Figure 3]. p53 overexpression and decreased expression of p63 were correlated with high tumor grade (p = 0.0002 and 0.046, respectively) and TNM stage (p = 0.017 and 0.012, respectively) [Table 2].
|Figure 2: p53 immunohistochemical expression. (A) diffuse nuclear staining of tumor cells (p53 200×). (B) p53 immunostaining in less than 10% of tumor cells (p53 200×).|
Click here to view
|Figure 3: p63 immunohistochemical expression. (A) strong and diffuse nuclear staining of neoplastic urotlelial cells in low grade tumor (p63 200×). (B) heterogenous immunoreactivity in high grade tumor (p63 200×).|
Click here to view
3.3. Association of HER2 expression with p53 and p63 expression
In a statistical analysis of the association between HER2 expression and p53/p63 expression, HER2 overexpression was correlated to a decreased expression of p63 (p = 0.037) but not with p53 overexpression (p = 0.350) [Table 3].
|Table 3: Association of immunohistochemical HER2 expression with p53 and p63 expression.|
Click here to view
3.4. Multivariate analysis of combined variables incorporating pathologic characteristics
In a multivariate analysis considering tumor grade, decreased expression of p63 and TNM stage as co-variables, HER2 overexpression was correlated with tumor grade (p = 0.006) but not with decreased expression of p63 and TNM stage.
| 4. Discussion|| |
In this study, 151 primary urothelial bladder carcinomas from Tunisian population were screened for HER2 expression and its correlation with p53 and p63 expression. To our knowledge, this is the first study to analyse immunohistochemical correlations of Her-2 with p53 and p63. HER2 is overexpressed in 9.3% of tumor samples which is comparable to rates of 9.2 (tumors 2+ and 3+) and 5.1% (tumors 3+) reported by Laé et al. . But this rate is lower than reported in several previous studies ranging from 21.7% to 80% ,,,,,,,,. Several hypotheses could explain these wide variations, as well as the relatively low rate of HER2 overexpression reported in our series. One of the major issues is the variability in immunohistochemistry assays, related to the heterogeneity between kits, antibodies, protocols, interpretations of staining or cut-off values. Scoring systems are variable and there is no consensus on the definition of HER2 overexpression in bladder carcinoma. Most authors used criteria of Wolff et al. reported for breast carcinoma (ASCO scoring system) .
In our study only tumors scored 3+ were considered overexpressing HER2. We consider that tumors scored 2+ should not be considered as overexpressing Her-2 without demonstration of HER2 gene amplification by in situ hybridization technique. In fact, literature data showed that the majority of cases scored 2+ are not amplificated by in situ hybridisation. In the study of Laé et al., all cases scored 2+ (n = 42) were negative by fluorescent in situ hybridization (FISH) technique . Moreover, Caner et al. noted that only 2 among 9 cases were amplificated by FISH and 4 among 12 cases were amplificated by real-time quantitative PCR for HER2 status .
P53 overexpression in urothelial carcinoma was reported in 30.8–60% ,. Some investigators noted a prognostic significance for p53 staining in both univariate and multivariate analysis ,,,. Shariat et al.  demonstrate that p53 is the strongest predictor marker of bladder carcinoma outcome in patient undergoing radical cystectomy. In our series p53 was overexpressed in 31.8% of tumors and was correlated to higher tumor grade and TNM stage. p63 is a homologue of the p53 tumor suppressor gene, that encodes multiple proteins that may either transactivate p53 responsive genes (Tap63) or act as a dominant negative factor toward p53 (deltaNp63) . p63 is constitutively expressed in the basal cell compartment of the stratified epithelium, including the urothelium, in which deltaNp63 is the predominant isoform expressed . p63 is decreased in most invasive cancers whereas papillary superficial tumors maintain its p63 expression . In urothelial carcinoma, decreased deltaNp63 expression is associated with more advanced disease and poorer prognosis ,,,. In our series decreased expression of p63 was associated with higher grade and TNM stage.
In our study, HER2 overexpression was correlated with decreased expression of p63 in univariate analysis. This correlation was lost on multivariate analysis. In fact HER2 overexpression was significantly related to tumor grade but not with TNM stage and p63 expression.
| 5. Conclusion|| |
In conclusion, HER2 was overexpressed in 9.3% of urothelial carcinoma in the current study, and was strongly correlated with high tumor grade. The development of target therapies using anti-HER2 and the identification of patients who may benefit from those therapies need further studies.
Conflict of interest
We have no conflict of interest to declare.
| References|| |
Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer incidence in five continents. Lyon: IARC Scientific Publications; 2007.
Hsairi M, Fakhfakh R, Ben Abdallah M, Jlidi R, Sellami A, Zheni S, et al. Assessment of cancer incidence in Tunisia 1993-1997. Tunisie Medicale 2002;80:57-64.
Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU International 2010;106:1216-22.
Caner V, Turk NS, Duzcan F, Tufan NL, Kelten EC, Zencir S, et al. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathology Oncology Research 2008;14:261-6.
Gandour-Edwards R, Lara Jr PN, Folkins AK, LaSalle JM, Beckett L, Li Y, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002;95:1009-15.
Hansel DE, Swain E, Dreicer R, Tubbs RR. HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. American Journal of Clinical Pathology 2008;130:274-81.
sHussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara Jr PN, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. Journal of Clinical Oncology 2007;25:2218-24.
Jalali Nadoushan MR, Taheri T, Jouian N, Zaeri F. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. Urology Journal 2007;4:151-4.
Matsubara H, Yamada Y, Naruse K, Nakamura K, Aoki S, Taki T, et al. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization. Oncology Reports 2008;19:57-63.
Naruse K, Yamada Y, Nakamura K, Aoki S, Taki T, Zennami K, et al. Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder. Oncology Reports 2010;23:1577-83.
Olsson H, Fyhr IM, Hultman P, Jahnson S. HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder. Scandinavian Journal of Urology and Nephrology 2012;46:102-7.
Simonetti S, Russo R, Ciancia G, Altieri V, De Rosa G, Insabato L. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. International Journal of Surgical Pathology 2009;17:198-205.
Skagias L, Politi E, Karameris A, Sambaziotis D, Archondakis A, Vasou O, et al. Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years’ research. Journal of BUON 2009;14:457-62.
Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Annals of Oncology 2010;21:815-9.
Fukushima H, Koga F, Kawakami S, Fujii Y, Yoshida S, Ratovitski E, et al. Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway. Cancer Research 2009;69:9263-70.
Karni-Schmidt O, Castillo-Martin M, Shen TH, Gladoun N, Domingo-Domenech J, Sanchez-Carbayo M, et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. American Journal of Pathology 2011;178:1350-60.
Koga F, Kawakami S, Kumagai J, Takizawa T, Ando N, Arai G, et al. Impaired Delta Np63 expression associates with reduced betacatenin and aggressive phenotypes of urothelial neoplasms. British Journal of Cancer 2003;88:740-7.
Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. Journal of Clinical Oncology 2004;22:1014-24.
Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. American Journal of Pathology 2002;161: 1199-206.
Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC; 2004.
Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Weinheim: Wiley; 2009.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology 2007;25:118-45.
Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 2004;63:1079-83.
Bernardini S, Adessi GL, Billerey C, Chezy E, Carbillet JP, Bittard H. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. Journal of Urology 1999;162:1496-501.
Tiguert R, Bianco Jr FJ, Oskanian P, Li Y, Grignon DJ, Wood Jr DP, et al. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. Journal of Urology 2001;166:2155-60.
Bernardini S, Billerey C, Martin M, Adessi GL, Wallerand H, Bittard H. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma Journal of Urology 2001;165:42-6.
Shiina H, Igawa M, Shigeno K, Yamasaki Y, Urakami S, Yoneda T, et al. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Oncology 1999;56:239-47.
Shiina H, Igawa M, Yagi H, Urakami S, Yoneda T, Shirakawa H, et al. Immunohistochemistry of p53 protein in transitional-cell carcinoma of the bladder using an image analyzer. Oncology 1996;53:233-40.
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2], [Table 3]
|This article has been cited by|
||Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer
| ||Aziza E. Abdelrahman,Hayam E. Rashed,Ehab Elkady,Eman A. Elsebai,Ahmed El-Azony,Ihab Matar |
| ||Annals of Diagnostic Pathology. 2019; |
|[Pubmed] | [DOI]|
||The Survey of Her2/neu Expression and It’s Correlation with Some Pathological Factors in Urothelial Bladder Tumors
| ||Samane Danaei,Seyed Hamid Madani,Sedigheh Khazaei,Babak Izadi,Elahe Saleh,Soraya Sajadimajd |
| ||Iranian Red Crescent Medical Journal. 2018; In Press(In Press) |
|[Pubmed] | [DOI]|
||Human epidermal growth factor receptor 2 expression in micropapillary urothelial carcinoma of the bladder: an analysis of 27 cases
| ||Abigail L. Goodman,Adeboye O. Osunkoya |
| ||Human Pathology. 2016; 57: 160 |
|[Pubmed] | [DOI]|
||The prognostic significance of p53, p63 and her2 expression in non-muscle-invasive bladder cancer in relation to treatment with bacille Calmette–Guerin
| ||Raafat Hegazy,Mostafa kamel,Emad A. Salem,Neveen A. Salem,Amr Fawzy,Ahmed Sakr,Ola El-farargy,Nashwa Nawar,Ahmed El-atar,Ashraf M.S. Shahin,Abdelmonem Hegazy |
| ||Arab Journal of Urology. 2015; 13(3): 225 |
|[Pubmed] | [DOI]|
||Expression of c-erb-B2 gene in bladder cancer of Egyptian patients and its correlation with p53 and bcl-2
| ||Saber A. Sakr,Hoda A. Mahran,Ahmed M. Fahmy,Meirhan A. El-Kholy,Mahmoud Meawad |
| ||Biomedicine & Pharmacotherapy. 2015; 76: 73 |
|[Pubmed] | [DOI]|
||HER2 expression status in diverse cancers: review of results from 37,992 patients
| ||Min Yan,Maria Schwaederle,David Arguello,Sherri Z. Millis,Zoran Gatalica,Razelle Kurzrock |
| ||Cancer and Metastasis Reviews. 2015; 34(1): 157 |
|[Pubmed] | [DOI]|